FLT3 and acute myeloid leukemia: In NMA, gilteritinib showed the highest probability for improved prognosis.<h4>Conclusions</h4>FLT3i safely improved prognosis in induction/reinduction stage of <i>FLT3</i>(+) AML and further boosted survival benefits from allo-HSCT as maintenance therapy, suggesting better prognosis if FLT3i is combined before and after allo-HSCT.